Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: Role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors

Circulation

Volumn 97, Issue 2, 1998, Pages 181-187

  Yang, Zhihong ^b   Oemar, Barry S ^b   Carrel, Thiery ^b   Kipfer, Beat ^b   Julmy, Friedgard ^b   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Cells; Enzymes; Growth substances; Muscle, smooth; Vessels

Indexed keywords

CYCLIN DEPENDENT KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INTERNAL MAMMARY ARTERY; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; VASCULAR SMOOTH MUSCLE;

EID: 0031890233     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.2.181     Document Type: Article

References (59)

1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LAR, Gill CC, Taylor PC, Sheldon WC, Proudfit WL. Influence of the internal mammary artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314:1-6.
2. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal thoracic-artery grafts: effects on survival over a 15-year period. N Engl J Med. 1996;334:216-219.
3. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, Von Segesser L, Yang Z, Turina M, Grädel G, Weber E, Bühler FR. Difference between endothelium-dependent relaxations in arterial and in venous coronary bypass grafts. N Engl J Med. 1988;319:462-467.
4. Yang Z, Stulz P, von Segesser L, Bauer E, Turina M, Lüscher TF. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet. 1991;337:939-943.
5. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J. 1989;10:273-280.
6. Kalan JM, Roberts WC. Comparison of morphologic changes and luminal sizes of saphenous vein and internal mammary artery after simultaneous implantation for coronary arterial bypass grafting. Am J Cardiol. 1987;60:193-196.
7. Sims FH. A comparison of coronary and internal mammary arteries and implications of the results in the etiology of arteriosclerosis. Am Heart J. 1983;105:560-566.
8. Schwarz SM, DeBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
10. Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol. 1993;2:179S-186S.
11. Barboriak JJ, Pintar K, Korns ME. Atherosclerosis in aorto-coronary vein grafts. Lancet. 1974;2:621-624.
12. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
13. Jawien A, Bowen-Pope DF, Lindnet V, Schwarz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
14. Israel DH, Adams PC, Chesebro JH, Fuster V. Antithrombotic therapy in the coronary vein graft patient. Clin Cardiol. 1991;14:283-295.
15. Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PAM, Repetto S, DeServi S, Varani E, for the STARC Investigators. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coro- nary angioplasty: results of the randomized, double-blind STARC study. Circulation. 1994;90:2710-2715.
16. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-676.
17. Bochaton-Piallat ML, Ropraz P, Gabbiani F, Gabbiani G. Phenotypic heterogeneity of rat arterial smooth muscle cell clones: implications for the development of experimental intimal thickening. Arterioscler Thromb Vasc Biol. 1996;16:815-820.
18. Majack RA, Grieshaber NA, Cook CL, Weiser MCM, McFall RC, Grieshaber SS, Reidy MA, Reilly CF. Smooth muscle cells isolated from the neointima after vascular injury exhibit altered responses to platelet-derived growth factor and other stimuli. J Cell Physiol. 1996;167:106-112.
19. Okamoto E, Suzuki T, Aikawa M, Imataka K, Fujii J, Kuroo M, Nakahara KI, Hasengawa A, Yazaki Y, Nagai R. Diversity of the synthetic-state smooth muscle cells proliferating in mechanically and hemodynamically injured rabbit arteries. Lab Invest. 1996;74:120-128.
20. Chamley-Campbell JH, Campbell GR, Ross R. Phenotype-dependent responses of cultured aortic smooth muscle to serum mitogens. J Cell Biol. 1981;89:379-383.
21. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Prof Natl Acad Sci U S A. 1993;90:5889-5892.
22. Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 1993;268:17896-17901.
23. mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol. 1992;6:845-854.
24. Pagés G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouysségur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319-8323.
25. Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059-1065.
26. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
27. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
28. Hunter T, Pines J. Cyclins and cancer II: cycliu D and CDK inhibitors come of age. Cell 1994;79:573-582.
29. Hannon GJ, Beach D. p 15INK4B is a potential effector of TGF-b induced cell cycle arrest. Nature. 1994;371:257-261.
30. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin/CDK4. Nature. 1993;366:704-707.
31. Mirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p 18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995;15:2672-2681.
32. Harper JW, Adann GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cydin-dependent kinases. Cell. 1993;75:805-816.
33. Toyoshima H, Hunter T. p27, a novel inhibitor of G1cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
34. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9:650-662.
35. Polyak K, Lee MH, Erdjument-Bromage H. Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator ot extracellular antimitogenic signals. Cell. 1994;78:59-66.
36. KIPI synthesis by platelet-derived growth factor in BALB/c3T3 cells. Mol Cell Biol. 1996;16:4327-4336.
37. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M, Massague J, Crabtree G, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
38. Predel HG, Yang Z, Von Segesser L, Turina M, Bühler FR, Lüscher TF. Implication of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet. 1992;340:878-879.
39. Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;88:832-836.
40. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:7.3-7.84.
41. Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Friedgard J, Joch H, Gafner V, Aleksic I, Althaus U, Lüscher TF. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels: implication for venous bypass graft failure. Circulation. 1997;95:1870-1876.
42. Sadoshima J, Qiu Z, Morgan JP, Izumo S. Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. Circ Res. 1995;76:1-15.
43. Heldin CH. Structure and function studies on platelet-derived growth factor. EMBO J. 1992;11:4251-4259.
44. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factors. Cell. 1986;46:155-169.
45. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. Two different subunits associate to create isoformspecific platelet-derived growth factor receptors. J Biol Chem. 1989;264:8771-8778.
46. Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ, Bowen-Pope DF. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988;240:1529-1531.
47. Nishio E, Fukushima K, Shiozaki M, Watanabe Y. Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Biochem Biophys Res Commun. 1996;22:1163-1168.
48. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 1994;23:32033-32036.
49. Lubinus M, Meier KE, Smith EA, Cause KC, LeRoy C, Trojanowska M. Independent effects of platelet-derived growth factor isofonns on mitogenactivated protein kinase activation and mitogenesis in human dermal fibroblasts. J Biol Chem. 1994;269:9822-9825.
50. Wilkie N, Morton C, Hg LL, Boarder MR. Stimulated mitogen-activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II. J Biol Chem. 1996;271:32447-32453.
51. Kondo T, Inui H, Konishi F, Inagami T. Phospholipase D mimics platelet-derived growth factor as a competence factor in vascular smooth muscle cells. J Biol Chem. 1992;267:23609-23616.
52. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;188:257-264.
53. Koide M, Kawahara Y, Tsuda T, Ishida Y, Shii K, Yokoyama M. Endothelin-1 stimulates tyrosine phosphorylation and the activities of two mitogen-activated protein kinases in cultured vascular smooth muscle cells. J Hypertens. 1992;10:1173-1182.
54. Kribben A, Wieder ED, Li X, vanPutten V, Granot Y, Schrier RW, NemmenofF RA. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Ant J Physiol. 1993;265(Cell Physiol 34):C939-C945.
55. Luo Y, Marx S, Kiyokawa H, Koff A, Massagué J, Marks A. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol. 1996;16:6744-6751.
56. Hengst L, Reed SI. Translational control of p27Kjp1 accumulation during the cell cycle. Science. 1996;271:1861-1864.
57. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996;272:877-880.
58. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor P27. Science. 1995;269:682-685.
59. Lui M, Lee MH, Cohen M, Bommakanti Freedman LP. Transcriptional activation of the Cd inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10:142-153.